Why Canopy Growth (TSX:WEED) Stock Jumped on Thursday

Canopy Growth (TSX:WEED)(NYSE:CGC) stock’s latest acquisition sees a return to the strategy of preparing for U.S. legalization.

| More on:

Cnaopy Growth (TSX:WEED)(NYSE:CGC) announced the company will acquire Wana Brands, which currently holds the top position of edibles in North America.

What happened?

Canopy Growth stock purchased Wana Brands in an agreement to make an all-cash deal of US$297.5 million. It would then acquire all three call option agreements of Mountain High Products, Wana Wellness, and the Cima Group.

Wana currently makes gummies in Colorado, distributing them to 12 states and across Canada. Wana believes by the end of 2022, this should increase to 20 states.

The deal marks yet another that would see Canopy Growth stock acquire a company upon federal legalization. But it’s not just the U.S. where the deal will help. Wana Brands has a licensing agreement with London, Ont. edibles-maker Indiva. Indiva currently has about 50% of the market share of legal cannabis edibles sold in Canada.

So what?

As mentioned, this is yet another deal to mark Canopy Growth stock and its move into the United States. However, it hasn’t make a deal like this in quite some time. The last deal it made was with Supreme Cannabis back in April for US$435 million, but this focused on the highly profitable area of vapes.

The Wana deal, however, is more like the major deal with Acreage Holdings back in 2019, before the market crash. That deal, once U.S legalization is complete, would sit at US$3.4 billion.

Now what?

While the deal is an important one, it’s unlikely to have analysts change their ideas of the immediate future of Canopy Growth stock. Analysts continue to believe Canopy Growth will continue to fall short of its goal to make a profit — not just now, but for several quarters.

That being said, the company seems to be on the right path. Since Chief Executive Officer David Klein took over the position in January 2020, there has been a huge restructuring of Canopy Growth stock. Layoffs, facility closings, and production stoppages all came even before the pandemic. This in a hope to convince investors it’s taking profit seriously.

Fool contributor Amy Legate-Wolfe owns shares of Canopy Growth Corp. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »